Chromium-based ethylene trimerization catalyst precursors ((PNP OMe - d 12 )CrPh 3 ( 4 ) and (PNP OMe - d 12 )CrPh 2 Cl ( 7 )) having a bis(diphenylphosphino)amine ligand ( o- CD 3 OC 6 H 4 ) 2 PN(CH 3 )P( o- CD 3 OC 6 H 4 ) 2 ((PNP OMe - d 12 ) = 1 ) have been prepared and characterized. A thioether analogue ( o- CD 3 SC 6 H 4 ) 2 PN(CH 3 )P( o- CD 3 SC 6 H 4 ) 2 ((PNP SMe - d 12 ) = 2 ) and its triphenylchromium complex (PNP SMe )CrPh 3 ( 5 ) have also been synthesized. The solid-state structures of 4 and 7 display octahedral geometries with a κ 3 -(P,P,O) coordination of PNP OMe ligands having chromium−oxygen bond lengths of 2.29−2.44 Å. Compound 5 differs, exhibiting (S,P,S)-κ 3 coordination of the PNP SMe ligand. The deuteromethyl groups allow for 2 H NMR characterization of these paramagnetic complexes in solution. Dynamic exchange processes occur in solution at room temperature to render all four of the methoxy or thioether groups equivalent on the 2 H NMR time scale; two distinct coalescence processes are observed by variable-temperature 2 H NMR spectroscopy for all compounds. The neutral species 4 and 7 react with ethylene (1 atm) by insertion into chromium−phenyl bonds with the release of styrene and ethylbenzene, but 1-hexene is not observed under these conditions. Activation of 4 by protonation and activation of 7 by halide abstraction in the presence of ethylene provide active trimerization catalysts that give turnover numbers for 1-hexene as high as 3000 mol 1-hexene·mol - 1 Cr. These catalysts display comparable activity and selectivity for 1-hexene compared to the original BP system, where the catalyst is generated in situ from CrCl 3 (THF) 3, 1, and MAO. Both the well-defined systems and the CrCl 3 (THF) 3 /PNP OMe /MAO system provide catalysts that undergo an initiation period followed by an apparent first-order decomposition process. Activated complexes 4 and 7 initiate trimerization primarily through ethylene insertion into the chromium−phenyl bond, followed by β-hydrogen elimination and reductive elimination to give the active species, rather than via reductive elimination of biphenyl.
No takes yet. Share an insight, caveat, or question.
Schofer et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: